GET THE APP

..

Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Non Biologic Complex Drug Concept: Experiences with Iron Sucrose and Low Molecular Weight Heparin

Abstract

Jacques Rottembourg and Huub Schellekens

When the patent of a small molecule drug expires, generics may be introduced. They are considered herapeutically equivalent once pharmaceutical equivalence (i.e. identical active substances) and bioequivalence i.e. comparable pharmacokinetics) have been established in cross-over volunteer study. However this generic paradigm cannot be applied to complex drugs as biologics. For copies of biologics EMA, and FDA, have introduced  new regulatory bio-similar pathway which mandate clinical trials to show therapeutic equivalence. However for ome complex drugs, such as iron-carbohydrate drugs, low molecular weight heparins (named Non Biologic Complex Drugs [NBCD]), regulatory guidance is still mostly lacking. In this paper we will discuss therapeutic experiences with these different classes of complex drugs and their specificity, to provide scientific arguments for consideration for a new regulatory framework.

PDF

Share this article

Google Scholar citation report
Citations: 443

Journal of Blood & Lymph received 443 citations as per Google Scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward